Life Science REIT (LON:LABS) Earns “Buy” Rating from Berenberg Bank

Berenberg Bank restated their buy rating on shares of Life Science REIT (LON:LABS) in a report released on Thursday morning, MarketBeat.com reports. They currently have a GBX 57 ($0.76) target price on the stock.

Other equities research analysts have also issued research reports about the company. Shore Capital reissued a buy rating on shares of Life Science REIT in a research note on Thursday, September 26th. Jefferies Financial Group lowered their price objective on Life Science REIT from GBX 45 ($0.60) to GBX 36 ($0.48) and set a hold rating for the company in a research report on Friday, August 30th.

Life Science REIT Stock Down 2.5 %

Shares of LON:LABS opened at GBX 39 ($0.52) on Thursday. The company’s fifty day moving average is GBX 34.15 and its 200 day moving average is GBX 35.86. Life Science REIT has a 52 week low of GBX 31.30 ($0.42) and a 52 week high of GBX 74.20 ($0.99). The stock has a market cap of £136.50 million, a PE ratio of -650.00 and a beta of 0.08.

Life Science REIT Announces Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, October 31st. Stockholders of record on Thursday, October 3rd will be paid a dividend of GBX 1 ($0.01) per share. This represents a dividend yield of 3.11%. The ex-dividend date is Thursday, October 3rd. Life Science REIT’s dividend payout ratio (DPR) is -3,333.33%.